Disulfiram, as a candidate NF-?B and proteasome inhibitor, prevents endometriotic implant growing in a rat model of endometriosis

Basit Öğe Kaydı
dc.authorwosidDeniz, Rulin/HJY-8666-2023
dc.authorwosidBaykus, Yakup/HJY-8586-2023
dc.authorwosidÖZEROL, ELİF/AAA-6707-2021
dc.authorwosidersahin, aynur/AAH-6268-2019
dc.authorwosidÖzerol, İbrahim Halil/ABI-8015-2020
dc.contributor.authorCelik, O.
dc.contributor.authorErsahin, A.
dc.contributor.authorAcet, M.
dc.contributor.authorCelik, N.
dc.contributor.authorBaykus, Y.
dc.contributor.authorDeniz, R.
dc.contributor.authorOzerol, E.
dc.date.accessioned2024-08-04T20:57:42Z
dc.date.available2024-08-04T20:57:42Z
dc.date.issued2016
dc.departmentİnönü Üniversitesien_US
dc.description.abstractOBJECTIVE: Disulfiram (DSF) exerts its therapeutic effects through oxidative, proteasome, and nuclear factor kappa beta (NF-kappa B) pathways. The study was planned to test the impact of DSF on growing of endometriotic implants in rats with experimentally induced endometriosis. PATIENTS AND METHODS: Thirty rats were labeled as the control (n = 8), sham (n = 6), GnRH-agonist (n = 8) and the DSF (n = 8) groups. The rats in the group 3 exposed to single dose leuprolide acetate. The rats in group 4 were treated with DSF for 21 days. The serum activity of oxidant and antioxidant markers, total oxidant status (TOS), total antioxidant status (TAS), interleukin-1 beta, and tumor necrosis factora (TNF-alpha) were determined. Implants were processed for NF-kappa B, PCNA, and CD34 immunostaining. RESULTS: The serum concentration of malondialdehyde in the DSF group was significantly higher than those in other groups. The concentration of TAS, TNF-alpha, and interleukin-1 beta in the DSF group considerably decreased compared to control group. Following treatment with DSF while the percentage of Grade 1 and 2 implants increased the percentage of Grade 3 and 4 implants decreased. The implants disappeared totally in two cases in the DSF group and one case in the GnRH-agonist group. The mean H-Scores of implant NF-kappa B and PCNA in DSF treated animals were found to significantly lower than those of the control group. CONCLUSIONS: By decreasing NF-kappa B expression, angiogenesis, and cell proliferation DSF prevents the growth of endometriotic implants.en_US
dc.identifier.endpage4389en_US
dc.identifier.issn1128-3602
dc.identifier.issue20en_US
dc.identifier.pmid27831632en_US
dc.identifier.startpage4380en_US
dc.identifier.urihttps://hdl.handle.net/11616/102847
dc.identifier.volume20en_US
dc.identifier.wosWOS:000388238500028en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometriosisen_US
dc.subjectDisulfiramen_US
dc.subjectNF-kappa Ben_US
dc.subjectOxidative stressen_US
dc.titleDisulfiram, as a candidate NF-?B and proteasome inhibitor, prevents endometriotic implant growing in a rat model of endometriosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu